Myron S Cohen1, Ying Q Chen1, Marybeth McCauley1, Theresa Gamble1, Mina C Hosseinipour1, Nagalingeswaran Kumarasamy1, James G Hakim1, Johnstone Kumwenda1, Beatriz Grinsztejn1, Jose H S Pilotto1, Sheela V Godbole1, Suwat Chariyalertsak1, Breno R Santos1, Kenneth H Mayer1, Irving F Hoffman1, Susan H Eshleman1, Estelle Piwowar-Manning1, Leslie Cottle1, Xinyi C Zhang1, Joseph Makhema1, Lisa A Mills1, Ravindre Panchia1, Sharlaa Faesen1, Joseph Eron1, Joel Gallant1, Diane Havlir1, Susan Swindells1, Vanessa Elharrar1, David Burns1, Taha E Taha1, Karin Nielsen-Saines1, David D Celentano1, Max Essex1, Sarah E Hudelson1, Andrew D Redd1, Thomas R Fleming1. 1. From the Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill (M.S.C., M.C.H., I.F.H., J.E.); the Divisions of Vaccine and Infectious Disease (Y.Q.C., X.C.Z.) and Public Health Science (Y.Q.C.) and the Statistical Center for HIV/AIDS Research and Prevention (L.C.), Fred Hutchinson Cancer Research Center, and the Department of Biostatistics, University of Washington (T.R.F.) - both in Seattle; FHI 360, Washington, DC (M.M.), and Durham, NC (T.G.); Y.R. Gaitonde Center for AIDS Research and Education, Chennai (N.K.), and National AIDS Research Institute, Pune (S.V.G.) - both in India; University of Zimbabwe, Harare (J.G.H.); College of Medicine-Johns Hopkins Project, Blantyre, Malawi (J.K.); Instituto de Pesquisa Clinica Evandro Chagas (B.G.) and Hospital Geral de Nova Iguacu and Laboratorio de AIDS e Imunologia Molecular-IOC/Fiocruz (J.H.S.P.), Rio de Janeiro, and Servico de Infectologia, Hospital Nossa Senhora da Conceicao/GHC, Porto Alegre (B.R.S.) - both in Brazil; Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand (S.C.); Fenway Institute (K.H.M.) and Harvard School of Public Health (M.E.) - both in Boston; the Departments of Pathology (S.H.E., E.P.-M., S.E.H.) and Medicine (A.D.R.), Johns Hopkins University School of Medicine, the Department of Epidemiology, Bloomberg School of Public Health (T.E.T.), and Johns Hopkins Bloomberg School of Public Health (D.D.C.), Baltimore, and the Division of AIDS (V.E., D.B.) and Laboratory of Immunoregulation (A.D.R.), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda - both in Maryland; Botswana Harvard AIDS Institute, Gaborone (J.M.); Centers for Disease Control and Prevention (CDC) Division of HIV/AIDS Prevention/KEMRI-CDC Research and Public Health Collaboration HIV Research Branch, Kisumu, Kenya (L.A.M.); Perinatal HIV Research Unit (R.P.) and Clinical HIV Research Unit, Department of Medicine, Faculty of Health Scien
Abstract
BACKGROUND: An interim analysis of data from the HIV Prevention Trials Network (HPTN) 052 trial showed that antiretroviral therapy (ART) prevented more than 96% of genetically linked infections caused by human immunodeficiency virus type 1 (HIV-1) in serodiscordant couples. ART was then offered to all patients with HIV-1 infection (index participants). The study included more than 5 years of follow-up to assess the durability of such therapy for the prevention of HIV-1 transmission. METHODS: We randomly assigned 1763 index participants to receive eitherearly or delayed ART. In the early-ART group, 886 participants started therapy at enrollment (CD4+ count, 350 to 550 cells per cubic millimeter). In the delayed-ART group, 877 participants started therapy after two consecutive CD4+ counts fell below 250 cells per cubic millimeter or if an illness indicative of the acquired immunodeficiency syndrome (i.e., an AIDS-defining illness) developed. The primary study end point was the diagnosis of genetically linked HIV-1 infection in the previously HIV-1-negative partner in an intention-to-treat analysis. RESULTS:Index participants were followed for 10,031 person-years; partners were followed for 8509 person-years. Among partners, 78 HIV-1 infections were observed during the trial (annual incidence, 0.9%; 95% confidence interval [CI], 0.7 to 1.1). Viral-linkage status was determined for 72 (92%) of the partner infections. Of these infections, 46 were linked (3 in the early-ART group and 43 in the delayed-ART group; incidence, 0.5%; 95% CI, 0.4 to 0.7) and 26 were unlinked (14 in the early-ART group and 12 in the delayed-ART group; incidence, 0.3%; 95% CI, 0.2 to 0.4). Early ART was associated with a 93% lower risk of linked partner infection than was delayed ART (hazard ratio, 0.07; 95% CI, 0.02 to 0.22). No linked infections were observed when HIV-1 infection was stably suppressed by ART in the index participant. CONCLUSIONS: The early initiation of ART led to a sustained decrease in genetically linked HIV-1 infections in sexual partners. (Funded by the National Institute of Allergy and Infectious Diseases; HPTN 052 ClinicalTrials.gov number, NCT00074581 .).
RCT Entities:
BACKGROUND: An interim analysis of data from the HIV Prevention Trials Network (HPTN) 052 trial showed that antiretroviral therapy (ART) prevented more than 96% of genetically linked infections caused by human immunodeficiency virus type 1 (HIV-1) in serodiscordant couples. ART was then offered to all patients with HIV-1 infection (index participants). The study included more than 5 years of follow-up to assess the durability of such therapy for the prevention of HIV-1 transmission. METHODS: We randomly assigned 1763 index participants to receive either early or delayed ART. In the early-ART group, 886 participants started therapy at enrollment (CD4+ count, 350 to 550 cells per cubic millimeter). In the delayed-ART group, 877 participants started therapy after two consecutive CD4+ counts fell below 250 cells per cubic millimeter or if an illness indicative of the acquired immunodeficiency syndrome (i.e., an AIDS-defining illness) developed. The primary study end point was the diagnosis of genetically linked HIV-1 infection in the previously HIV-1-negative partner in an intention-to-treat analysis. RESULTS: Index participants were followed for 10,031 person-years; partners were followed for 8509 person-years. Among partners, 78 HIV-1 infections were observed during the trial (annual incidence, 0.9%; 95% confidence interval [CI], 0.7 to 1.1). Viral-linkage status was determined for 72 (92%) of the partner infections. Of these infections, 46 were linked (3 in the early-ART group and 43 in the delayed-ART group; incidence, 0.5%; 95% CI, 0.4 to 0.7) and 26 were unlinked (14 in the early-ART group and 12 in the delayed-ART group; incidence, 0.3%; 95% CI, 0.2 to 0.4). Early ART was associated with a 93% lower risk of linked partner infection than was delayed ART (hazard ratio, 0.07; 95% CI, 0.02 to 0.22). No linked infections were observed when HIV-1 infection was stably suppressed by ART in the index participant. CONCLUSIONS: The early initiation of ART led to a sustained decrease in genetically linked HIV-1 infections in sexual partners. (Funded by the National Institute of Allergy and Infectious Diseases; HPTN 052 ClinicalTrials.gov number, NCT00074581 .).
Authors: Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton Journal: N Engl J Med Date: 2015-07-20 Impact factor: 91.245
Authors: Tuan Le; Edwina J Wright; Davey M Smith; Weijing He; Gabriel Catano; Jason F Okulicz; Jason A Young; Robert A Clark; Douglas D Richman; Susan J Little; Sunil K Ahuja Journal: N Engl J Med Date: 2013-01-17 Impact factor: 91.245
Authors: Timothy B Hallett; Jared M Baeten; Renee Heffron; Ruanne Barnabas; Guy de Bruyn; Íde Cremin; Sinead Delany; Geoffrey P Garnett; Glenda Gray; Leigh Johnson; James McIntyre; Helen Rees; Connie Celum Journal: PLoS Med Date: 2011-11-15 Impact factor: 11.069
Authors: Marie-Claude Boily; Benoît Mâsse; Ramzi Alsallaq; Nancy S Padian; Jeffrey W Eaton; Juan F Vesga; Timothy B Hallett Journal: PLoS Med Date: 2012-07-10 Impact factor: 11.069
Authors: Anne Cori; Helen Ayles; Nulda Beyers; Ab Schaap; Sian Floyd; Kalpana Sabapathy; Jeffrey W Eaton; Katharina Hauck; Peter Smith; Sam Griffith; Ayana Moore; Deborah Donnell; Sten H Vermund; Sarah Fidler; Richard Hayes; Christophe Fraser Journal: PLoS One Date: 2014-01-15 Impact factor: 3.240
Authors: Myron S Cohen; M Kumi Smith; Kathryn E Muessig; Timothy B Hallett; Kimberly A Powers; Angela D Kashuba Journal: Lancet Date: 2013-10-23 Impact factor: 79.321
Authors: Kathryn E Muessig; Sara LeGrand; Keith J Horvath; José A Bauermeister; Lisa B Hightow-Weidman Journal: Curr Opin HIV AIDS Date: 2017-09 Impact factor: 4.283
Authors: David H Altreuter; Ameya R Kirtane; Tyler Grant; Cecilia Kruger; Giovanni Traverso; Andrew M Bellinger Journal: Expert Opin Drug Deliv Date: 2018-11-13 Impact factor: 6.648
Authors: Holly Janes; Lawrence Corey; Gita Ramjee; Lindsay N Carpp; Carl Lombard; Myron S Cohen; Peter B Gilbert; Glenda E Gray Journal: AIDS Res Hum Retroviruses Date: 2018-06-19 Impact factor: 2.205
Authors: Álvaro H Borges; Jacqueline Neuhaus; Shweta Sharma; James D Neaton; Keith Henry; Olga Anagnostou; Teresa Staub; Sean Emery; Jens D Lundgren Journal: J Infect Dis Date: 2019-01-07 Impact factor: 5.226
Authors: Robin M Nance; J A Chris Delaney; Jane M Simoni; Ira B Wilson; Kenneth H Mayer; Bridget M Whitney; Frances M Aunon; Steven A Safren; Michael J Mugavero; W Christopher Mathews; Katerina A Christopoulos; Joseph J Eron; Sonia Napravnik; Richard D Moore; Benigno Rodriguez; Bryan Lau; Rob J Fredericksen; Michael S Saag; Mari M Kitahata; Heidi M Crane Journal: Ann Intern Med Date: 2018-08-21 Impact factor: 25.391
Authors: Jennifer LeMessurier; Gregory Traversy; Olivia Varsaneux; Makenzie Weekes; Marc T Avey; Oscar Niragira; Robert Gervais; Gordon Guyatt; Rachel Rodin Journal: CMAJ Date: 2018-11-19 Impact factor: 8.262